Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development

CAR-T Digest - August 2020

4 Apr 2024: Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development

Caris Life Sciences partners with Merck KGaA to accelerate ADC development for cancer patients
Merck KGaA will provide upfront payment, research funding, and milestone payments up to $1.4 billion, along with royalties
Merck KGaA gains exclusive global license to develop, manufacture, and commercialize ADC therapeutics for selected targets
Caris Life Sciences utilizes the ADAPT Biotargeting platform and AI capabilities to discover novel targets for oncology therapies
Targets discovered by Caris can be pursued by Merck KGaA, which will handle preclinical and clinical research, as well as drug development and commercialization